South Korea Hemoglobinopathies Market Size & Outlook
South Korea hemoglobinopathies market, 2018-2030 (US$M)
Related Markets
South Korea hemoglobinopathies market highlights
- The South Korea hemoglobinopathies market generated a revenue of USD 243.5 million in 2022 and is expected to reach USD 680.0 million by 2030.
- The South Korea market is expected to grow at a CAGR of 13.7% from 2023 to 2030.
- In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
- Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.
Hemoglobinopathies market data book summary
| Market revenue in 2022 | USD 243.5 million |
| Market revenue in 2030 | USD 680.0 million |
| Growth rate | 13.7% (CAGR from 2022 to 2030) |
| Largest segment | Sickle cell disease |
| Fastest growing segment | Sickle cell disease |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
| Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.6% of the global hemoglobinopathies market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China hemoglobinopathies market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,635.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemoglobinopathies Market Scope
Hemoglobinopathies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Korea hemoglobinopathies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.26% in 2022. Horizon Databook has segmented the South Korea hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of hemoglobinopathies is relatively low in South Korea. However, increase in the number of immigrants from countries with high prevalence of these conditions is likely to increase the disease burden in the country.
As prevalence of thalassemia is very high in Southeast Asian population, it is expected to increase the number of cases of hemoglobinopathies in the country. In 2019, Emmaus Life Sciences, Inc. and South Korea-based Vivozon, Inc. entered into an equity investment, which is expected to improve commercialization of the sickle cell product called Endari.
Moreover, ongoing collaborations between organizations involved in developing therapies for hemoglobinopathies are also expected to contribute to the growth of the market. In January 2016, Emmaus Life Sciences, Inc. collaborated with Korea Bio Medical Science Institute (KBMSI) to develop and commercialize therapies for SCD treatment in South Korea.
Reasons to subscribe to South Korea hemoglobinopathies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Korea hemoglobinopathies market databook
-
Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea hemoglobinopathies market , including forecasts for subscribers. This country databook contains high-level insights into South Korea hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
South Korea hemoglobinopathies market size, by disease type, 2018-2030 (US$M)
South Korea Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
